LabGenomics hires Kwon Hyuk-jung, former EDGC AI·BI Executive Director, to strengthen genomic diagnostics capabilities

Global genetic molecular diagnostics specialist LabGenomics announced on the 5th that it has recruited Kwon Hyuk-jung, former EDGC AI (Artificial Intelligence) and BI (Bioinformatics) executive, as the head of LabGenomics' BI Analysis Office and Strategic Business Division, concurrently serving as an executive director.

Since 1998, Director Kwon worked for 19 years as a researcher in the IT and telecommunications fields at companies such as LG Electronics and SK Teletech. He is an IT expert with diverse development experience, mainly responsible for communication protocol and firmware development across various fields.

From 2016, he was in charge of EDGC's AI and BI sectors, leading the development of testing models based on NGS (Next-Generation Sequencing) and microarray technologies.

Recently, the importance of BI technology, which accurately and rapidly analyzes vast genomic data produced through sequencing in the NGS field and provides results, has been highlighted. Since last year, the company has strengthened its IT headquarters to enhance competitiveness in the IT sector, and with the recruitment of Director Kwon, an expert in the NGS testing field, it is expected to create strong synergy to reinforce competitiveness in the genomic diagnostics business.

Additionally, Director Kwon was responsible for designing and developing EDGC's new services, including the liquid biopsy pipeline, a non-invasive test that collects blood samples. He also concurrently served in the Medical Affairs role, acting as a bridge among operational staff, internal and external stakeholders, and researchers by handling overseas sales and presentations at international conferences.

A LabGenomics official stated, "Director Kwon will strengthen the company's capabilities by leveraging his extensive experience in various genomic diagnostic businesses such as NIPT (Non-Invasive Prenatal Testing) and liquid biopsy," adding, "We aim to leap forward as a global molecular diagnostics company by targeting the PGS (Personal Genetic Testing) market, including microbiome testing, alongside NIPT."

Meanwhile, the global market size of the genomic industry has recorded 33 trillion KRW last year, showing an average annual growth rate of 10.6% since 2017.

This content was produced with the assistance of AI translation services.